The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2021
-
Randomized Controlled Trial Multicenter Study
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. ⋯ Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).